标题
Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume 103, Issue 22, Pages 1665-1675
出版商
Oxford University Press (OUP)
发表日期
2011-09-14
DOI
10.1093/jnci/djr362
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Angiogenesis Inhibition in the Treatment of Prostate Cancer
- (2012) Ravi Madan et al. Anti-Cancer Agents in Medicinal Chemistry
- VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
- (2011) W.-K. You et al. CANCER RESEARCH
- The Current and Emerging Role of Immunotherapy in Prostate Cancer
- (2011) Ravi A. Madan et al. Clinical Genitourinary Cancer
- The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells
- (2011) Hans H. G. Verbeek et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Docetaxel-based combination therapy for castration-resistant prostate cancer
- (2010) M. D. Galsky et al. ANNALS OF ONCOLOGY
- Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL
- (2010) Yu-Hsuan Shao et al. ARCHIVES OF INTERNAL MEDICINE
- Efficacy of c-Met inhibitor for advanced prostate cancer
- (2010) William H Tu et al. BMC CANCER
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
- (2010) A. Zoubeidi et al. CLINICAL CANCER RESEARCH
- Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
- (2010) W. D. Stein et al. CLINICAL CANCER RESEARCH
- A New Therapy Paradigm for Prostate Cancer Founded on Clinical Observations
- (2010) E. Efstathiou et al. CLINICAL CANCER RESEARCH
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Therapeutic targeting of the prostate cancer microenvironment
- (2010) Maria Karlou et al. Nature Reviews Urology
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails
- (2010) Y Niu et al. ONCOGENE
- Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
- (2009) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis
- (2009) T Koreckij et al. BRITISH JOURNAL OF CANCER
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
- (2009) James L. Gulley et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
- (2009) L. Fong et al. CANCER RESEARCH
- Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
- (2009) G. Attard et al. CANCER RESEARCH
- Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2009) E. Y. Yu et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Outcomes of Localized Prostate Cancer Following Conservative Management
- (2009) Grace L. Lu-Yao JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer
- (2009) William L. Dahut et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease
- (2009) Elahe A. Mostaghel et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer
- (2008) Kim N Chi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells
- (2008) Hewang Li et al. JOURNAL OF CLINICAL INVESTIGATION
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- The tumor microenvironment and its role in promoting tumor growth
- (2008) T L Whiteside ONCOGENE
- CYP17 inhibition as a hormonal strategy for prostate cancer
- (2008) Alison HM Reid et al. Nature clinical practice. Urology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started